Association between contrast-induced nephropathy and CHA2DS2-VASc score in patient with non-ST elevation myocardial infarction after percutaneous coronary intervention

Sohel Siddike; M. Mamunur Rashid; Pradip Kumar Karmakar; M. Abdul Hamid; AFM Rezaul Islam; Saurav Das; Atikur Rahman; Mohammad Faridul Hoque; Shameem Aktar; M. Sawkat Hossan

doi:10.18203/2320-6012.ijrms20240205

Authors

Sohel Siddike Department of Cardiology, Chattogram Medical College Hospital, Chattogram, Bangladesh
M. Mamunur Rashid Department of Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh
Pradip Kumar Karmakar Department of Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh
M. Abdul Hamid Chattogram Medical College Hospital, Chattogram, Bangladesh
AFM Rezaul Islam Department of Cardiology, Sylhet MAG Osmani Medical College Hospital, Sylhet, Bangladesh
Saurav Das Department of Cardiology, Chittagong Medical College, Chattogram, Bangladesh
Atikur Rahman Department of Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh
Mohammad Faridul Hoque Department of Cardiology, Colonel Maleque Medical College, Manikganj, Bangladesh.
Shameem Aktar Department of Cardiology, M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh
M. Sawkat Hossan Chittagong Medical College, Chattogram, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20240205

Keywords:

CHA2DS2-VASc score, CIN, NSTEMI, PCI

Abstract

Background: Contrast-induced nephropathy (CIN) is a recognized complication in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). CHA2DS2-VASc score, commonly employed in clinical settings, shares similar risk factors for CIN development. This cross-sectional observational study investigated the association between CHA2DS2-VASc score and CIN post-PCI in non-ST segment elevated myocardial infarction (NSTEMI) patients.

Methods: Over one year (April 2019 to March 2020), 100 NSTEMI patients undergoing PCI at the national institute of cardiovascular diseases (NICVD), Dhaka, were included. Patients were categorized into two groups based on CHA2DS2-VASc scores (≥4, group I; <4, group II). CIN assessment utilized post-procedural serum creatinine within 48 hours, with statistical analysis performed using SPSS version 20.0.

Results: Group I exhibited a significantly higher CHA2DS2-VASc score (4.15±1.35 vs. 2.25±0.92 in group II). Post-procedural serum creatinine was notably elevated in CHA2DS2-VASc score ≥4 (1.98±0.46 vs. 1.46±0.27, p<0.001). A CHA2DS2-VASc score cut-off ≥4 predicted CIN with 84.6% sensitivity, 55.2% specificity (AUC 0.83, CI: 0.743-0.90, p<0.001).

Conclusions: This study establishes a significant association between CHA2DS2-VASc score and CIN in NSTEMI patients post-PCI, suggesting its potential utility in predicting CIN risk in this population.

Metrics

Metrics Loading ...

References

Benziger CP, Roth GA, Moran AE. The Global Burden of Disease Study and the Preventable Burden of NCD. Global Heart. 2016;11(4):393-7.

Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930-36.

Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232-45.

Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.

Huang SS, Chen YH, Chan WL, Huang PH, Chen JW, Lin SJ. Usefulness of the CHADS2 score for prognostic stratification of patients with acute myocardial infarction. Am J Cardiol. 2014;114(9):1309-14.

Capodanno D, Rossini R, Musumeci G, Lettieri C, Senni M, Valsecchi O et al. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. Int J Cardiol. 2015;199:319-25.

Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-64.

Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47(1):254-61.

Brar SS, Shen AYJ, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9):1038-46.

Chou RH, Huang PH, Hsu CY, Leu HB, Huang SS, Huang CC et al. ‘CHADS2 score predicts risk of contrast-induced nephropathy in stable coronary artery disease patients undergoing percutaneous coronary interventions. J Formosan Med Asso. 2016;115(7):501-9.

Chaudhary AK, Pathak V, Kunal S, Shukla S, Pathak, P. ‘CHA2DS2-VASc score as a novel predictor for contrast-induced nephropathy after percutaneous coronary intervention in acute coronary syndrome. Indian Heart J. 2019;71(4):303-8.

Kurtul A, Yarlioglues M, Duran M. Predictive Value of CHA2DS2-VASC Score for Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome. Am J Cardiol. 2017;119(6):819-25.

Waybill MM, Waybill PN. Contrast Media-induced Nephrotoxicity: Identification of Patients at Risk and Algorithms for Prevention. J Vascular Interventional Radiol. 2001;12(1):3-9.

Patschan D, Buschmann I, Ritter O. Contrast-Induced Nephropathy: Update on the Use of Crystalloids and Pharmacological Measures. Int J Nephrol. 2018;5727309.

Cicek G, Yıldırım E. CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention. Kardiologia Polska. 2018;76(1):91-8.